Cortexin (Cortexin) – a polypeptide complex, neurological studies, clinical studies and limitations of scientific evidence

Cortexin (Cortexin) is the trade name for a preparation obtained from the brain tissue of animals, containing many polypeptide fractions. It is not a single peptide with an unambiguously defined amino acid sequence. The manufacturer describes it as a complex of water-soluble polypeptide fractions obtained from the cerebral cortex of cattle. The studies include laboratory experiments, animal experiments, and clinical trials regarding neurological diseases in humans. However, these sources differ significantly in terms of what conclusions can be drawn from them. 1

An additional challenge in reviewing the literature is the very name „cortexin”. It also appears in basic studies concerning a separate, natural membrane protein. These publications should not be taken as evidence regarding a commercial product. A thorough analysis requires first distinguishing between these two meanings, and only then interpreting the results of the studies. 2

What is Cortexin? Names, synonyms and identity

The most important question at the beginning of the analysis is not solely whether a given name appears in the scientific database, but rather what the material means in a specific source. The trade name, the biological protein, and the general term “peptides derived from the cerebral cortex” may use similar terminology, even though they refer to different chemical entities.

The lack of distinction between these meanings can artificially increase the apparent number of studies and lead to the inclusion of unrelated molecular results in a clinical study article.

Repeated searches for literature should therefore include an analysis of titles, methods, product descriptions, and the populations studied, rather than simply counting all instances of the word „Cortexin”. Russian names and their transliterations can increase the number of found publications, but each of them requires checking whether it refers to the same preparation.

The recognizable trade name is only the first step in establishing the connection between the publication and the product under analysis.

The names Cortexin, Cortexin® and Кортексин (in Russian) refer to the commercial preparation discussed in this article. The manufacturer identifies it as a polypeptide product derived from the cerebral cortex and presents it as a prescription-only drug on the market, for which its documentation is available. Such a product description does not confirm its marketing authorization in all countries. 1

The commercial preparation should not be confused with the protein associated with neurons described in a 1993 publication titled „Identification of cortexin: a novel, neuron-specific, 82-residue membrane protein enriched in rodent cerebral cortex”.

This publication concerns a unit studied in molecular biology, and not a clinical study of a tissue extract available on the market. The similarity of the names does not confirm identical composition or equivalence of the evidence. 2

Cerebrolysin and Actovegin should also be distinguished from Cortexin. Comparative experiments involving these preparations do not make them synonymous or imply that the clinical results of one product can be automatically attributed to the other. These are separately identified materials whose production processes and composition require a separate characterization. 3

Before attributing the test result to Cortexin, the relationship between the material used and the specific product being analyzed must be established.

Important information includes the manufacturer, formulation, route of administration, production period, and analytical specifications. The familiar trade name alone is not sufficient to establish that a different form of the product has been properly tested.

How is Cortexin classified? Peptide, protein, mixture, or other substance?

This classification is particularly important for those who encounter the term „Cortexin peptide”. In common usage, it may suggest a single molecule with a predictable amino acid sequence. However, in the case of a commercial preparation, it is more precise to speak of peptide fractions or a polypeptide complex.

This distinction affects the way identity, purity, biological activity, and experimental repeatability are assessed.

In the case of purified peptide, researchers can often determine the sum total pattern, stereochemistry, terminal groups, and the appropriate reference pattern. Complex extracts are usually described using information about the manufacturing process, mass distribution of molecules, composition profiles, and quality control criteria.

These are different analytical approaches that should not be used interchangeably without proper justification.

Chemically, the commercial preparation is best classified as a mixture of tissue origin containing peptides or polypeptides. It has not been determined to be a single purified protein, a single synthetic peptide with a specific sequence, or a single molecule that acts selectively on a specific receptor.

The term „polypeptide” describes the nature of the components, but does not constitute evidence of the existence of a single, strictly defined molecular unit. 1

This classification directly affects the way the pharmacology of a drug is described. A defined synthetic peptide can often be associated with a single sequence, a defined molecular mass, and an estimate of exposure to a specific component.

The tissue-derived product, on the other hand, requires characterization of the breakdown of its components, their relative amounts, and the repeatability of the composition between production batches.

The presence of many ingredients does not preclude conducting valuable scientific research. However, it is crucial that the identity and quality of the preparation have been determined sufficiently precisely so that the results can be reproduced and linked to the current formulation.

The term „mixture” is a chemical classification, not an independent assessment of the effectiveness or ineffectiveness of a product.

Regulatory descriptions must also refer to a specific product and jurisdiction. The manufacturer's documentation helps determine which product is being offered; however, confirmation of the current marketing authorization in a given country requires verification of the official drug registration records.

In this review, it is not assumed that Cortexin has a confirmed marketing authorization worldwide.

Cortexin structure and composition – what has been established?

The lack of a complete amino acid sequence is not a minor omission that can be remedied by copying the pattern from another entry in the database.

This results from the difference between the defined molecule and a preparation containing many types of peptides. Even if it were possible in the future to determine the sequences of some components, the identity and proportions of the remaining fractions would still be important for the characteristics of the entire product.

Analytical techniques can answer complementary questions. Chromatographic profiles allow for the comparison of production batches; mass spectrometry helps characterize individual molecular units; targeted tests can measure specific markers, if appropriate samples are available.

None of these results alone proves that the preparation produces a specific clinical effect. The analytical profile used in quality control supports the material’s characteristics, whereas a claim of efficacy requires a separate experimental comparison.

The manufacturer’s information describes a collection of polypeptide fractions with a low molecular weight, rather than a single molecule with a disclosed sequence. Therefore, it does not justify assigning the entire preparation „Cortexin” to a single summary formula or a single molecular weight. 1

The interpretation of the composition requires distinguishing three levels.

The first is the source tissue. The second is the extracted and processed active fraction. The third is the finished formulation, which also includes the additional ingredients required for the specific form of the product.

Determining the origin of the tissue does not mean the full identification of the other two levels.

Even a complete list of amino acids does not allow identifying all the components of the mixture. It describes the building blocks, but not necessarily their sequence, the length of the chains, or the relative distribution between the molecules.

Similarly, the result of determining the total content of peptides does not indicate which components are responsible for the specific biological effect.

A rigorous compositional study should present repeatable analytical profiles and, where possible, identify the relevant components.

It should also explain which properties are controlled between production batches and whether their changes affect biological activity. This is particularly important when combining the results of mechanistic experiments with subsequent clinical formulations.

The heterogeneous composition causes additional difficulties during the interpretation of pharmacokinetic experiments. The detection of a marker associated with the given material does not in itself mean the identification of all intact active ingredients present in the target tissue.

Therefore, evidence regarding exposure must be interpreted in conjunction with the measurement method used and the chemical transformations of the labeled material.

Cortexin research – evidence in humans, animals and in the laboratory

The literature on people should be organized according to the clinical question, rather than treating all publications as a single group of equivalent evidence.

Studies on returning to neurological fitness after a stroke assess outcomes such as function and disability. Preclinical studies involving ischemia or seizures, however, analyze different biological systems.

Even within stroke research, the comparator group, the time taken to perform assessments, primary treatment, and formulation can all change the significance of the reported result.

The size of the sample is only one of the elements of the quality of evidence. A large study with an inadequate comparison group or incomplete reporting of results can leave important questions unanswered.

A smaller controlled study can, in turn, provide a useful, albeit less precise, estimate.

In the case of Cortexin, particular attention should be paid to whether the study compared active treatment with placebo or whether it compared two active formulations, using simulated placebo administration to maintain blinding.

Clinical studies on stroke

The outcomes of stroke treatment can be measured at several levels, including neurological disorders, the ability to perform daily activities, the degree of disability, and survival.

Improvements in one dimension should not automatically be presented as improvements in all other areas. Similarly, the difference observed during an early assessment does not necessarily indicate that the effect persists during subsequent observation.

If the study presents several results, the previously defined primary endpoint is important.

Secondary analyses can provide additional context, but their interpretation depends on the frequency of comparisons, the missing data, and whether the comparison was previously planned.

These issues are particularly important when only a summary or short report is available, because detailed methodological information may be missing in them.

A study published in 2008 presented a randomized, double-blind, placebo-controlled comparison involving 62 people with ischemic stroke.

The authors reported favorable neurological and functional outcomes. However, the small sample size and limited information available in the summary make it difficult to assess the precision of the effect, the rare adverse events, and the completeness of the reporting of results. 4

A multicenter publication from 2014 described a study involving 272 patients in which groups receiving different treatment regimens were compared with placebo.

The authors presented favorable clinical and pharmacoeconomic results. However, these conclusions should be evaluated with respect to the methods of participant allocation, baseline medical care, definition of endpoints, missing data, and estimates of differences between groups, rather than being based solely on the positive wording of the summary. 5

The more recent indexed publication describes a study involving 490 patients in which intravenous and intramuscular formulations of Cortexin were compared.

Both groups received active Cortexin, while placebo injections were used to mask the alternative route of administration.

This is a key methodological distinction. The term „controlled placebo” in the abstract does not mean that one of the groups did not receive active Cortexin.

The study concerns the comparison of formulations and cannot independently confirm its effectiveness in situations where Cortexin is not used. 6

In a more recent study comparing formulations, special attention was paid to the functional state after 90 days.

Such a comparison still requires careful statistical interpretation. Demonstrating equivalence or no less effective treatment requires a previously established margin and appropriate analysis, rather than merely similar results or the absence of a statistically significant difference.

A mere summary does not answer all the questions regarding the research project. 6

Independent evaluation of scientific evidence

Systematic reviews help to understand why a positive outcome of a single publication does not necessarily translate into a highly reliable clinical recommendation.

Review authors analyze the methods of research, the completeness of reporting, the consistency of results, and the significance of endpoints, rather than relying solely on a soundly argued conclusion.

Therefore, the 2023 review presents a different perspective than the manufacturer's description or the summary of a single clinical study.

The result of the overall analysis also depends on which data have been combined.

If the meta-analysis includes several different products, its aggregate result cannot be presented as the result of Cortexin itself.

Similarly, the signal regarding adverse events attributed to another product included in the analysis must remain linked to that specific product.

Correctly attributing results is essential to avoid both exaggerating the benefits and attributing unconfirmed harms.

The 2023 Cochrane systematic review independently evaluated the available evidence and pooled analyses, including one Cortexin study involving 272 participants alongside studies on Cerebrolysin.

In a combined mortality analysis, it was found that there is probably little or no difference in mortality for any reason.

This result is not an estimate of the effect that concerns only Cortexin.

The review authors rated the majority of areas of systematic error risk in the Cortexin study included as unclear and pointed out significant deficiencies in reporting results. The literature search conducted for the review preceded a newer study comparing formulations. 7

The signal of an increased number of serious adverse events that did not result in death discussed in the review concerned Cerebrolysin and should not be attributed to Cortexin.

Separation of products and results is necessary even when a systematic review combines related preparations in some analyses.

This assessment justifies caution regarding broad clinical claims, but it does not prove that every proposed effect is absent. 7

Animal studies and laboratory tests

Preclinical models help identify possible biological pathways and choose questions for further research.

However, experimentally induced ischemic damage in rodents differs from the complex circumstances of stroke in humans, which include underlying diseases, the time of treatment initiation, rehabilitation, and co-existing conditions.

A positive result in an animal therefore justifies further studies, rather than direct predictions of improvement in patients.

Comparative experiments involving several preparations derived from the brains of animals can be particularly useful for analyzing differences between products.

However, caution is required because similar effects do not indicate identical composition of the mixtures or the possibility of transferring the results of one preparation to another.

Information about funding and independent replication of studies should be considered in conjunction with the actual methods and results.

In a preclinical study from 2021, Cortexin was compared with Cerebrolysin and Actovegin in rat models of acute and chronic cerebral ischemia.

The authors presented neurological, tissue and biochemical results, and also conducted separate experiments regarding receptor binding and distribution in mice.

These are preclinical results, not direct evidence of improvement after a stroke or an increase in cognitive abilities in humans. The publication revealed commercial funding. 3

Additional experiments on animals analyzed indicators related to seizures and behavior.

These models can help formulate questions regarding neuronal signaling, but the route of administration, the type of experimental damage, the species, and the endpoints limit the possibility of generalizing clinical results.

In particular, administering the substance directly to brain cells does not determine what happens after using another administration route under clinical conditions. 8 9

In total, the sources include real clinical studies involving humans, as well as laboratory and animal studies.

Neither the claim that there are „exclusively animal studies” nor the statement that the effectiveness of Cortexin has been „fully confirmed in all neurological disorders” properly describes this literature.

Action mechanisms studied in the context of Cortexin

In the case of a mixture study, the mechanism of action includes two related tasks.

The first is determining which reactions the preparation causes in a specific experimental system. The second is identifying the components that may be responsible for these reactions.

Binding patterns with receptors or changes in tissue markers can provide information about the first issue, but do not resolve the second.

The mechanistic explanation becomes stronger when the responsible chemical entities, the appropriate exposure, and the functional consequences can be linked together.

The blood-brain barrier is another area that requires careful interpretation.

Detectable signals in the brain of mice after administration of labeled material do not necessarily mean that each peptide remained intact, penetrated the human brain tissue, or reached a concentration of pharmacological significance.

Distinguishing the intact active component from labeled metabolites is important when assessing claims regarding tissue distribution.

The mechanisms proposed in the literature include modulation of excitatory and inhibitory neurotransmission, processes related to oxidative stress, and responses to brain injury.

These hypotheses are more useful when they can be linked to specific experiments than when they are presented as a general claim that Cortexin „rehabilitates the brain”.

In an experimental study from 2021, researchers evaluated binding to a panel of receptors, including targets associated with glutamate and GABA, while simultaneously analyzing tissue and behavioral results.

Binding of the mixture to receptors does not identify the responsible sequence, does not determine whether each interaction produces the same functional effect, nor does it prove that the corresponding exposure occurs in humans. 3

In part of this study concerning tissue distribution, radiolabeled material was used and administered to mice.

The results support research on brain exposure, but they should not be presented as evidence that all intact components cross the blood-brain barrier in humans and reach effective concentrations.

This interpretation is influenced by the species, the stability of the marker, metabolism, and the identity of the components.

Measurements related to antioxidant pathways are of narrower significance than claims of clinical neurological improvement.

Changing the tissue marker may help in studying the biological pathway, but it does not confirm improvement in independence, survival, communication, or quality of life after a stroke.

These results require clinical measurements.

A similar distinction is necessary when interpreting the behavior of animals.

A better performance on a specific task may confirm an observation appropriate to the given model, but leaves uncertainty regarding the mechanism and its significance for humans.

Different results should be combined using evidence, not by further and increasingly broad assumptions.

Limitations of the scientific evidence regarding Cortexin

The most justified approach to the hierarchy of evidence distinguishes between manufacturer declarations, mechanistic studies, animal experiments, single clinical studies, and systematic reviews.

Each of these sources can provide information, but their value for the claim of benefit to the patient is not equal.

The biologically plausible mechanism does not eliminate the weakness of clinical comparison, and a positive test result does not automatically identify all active components of the mixture.

Another unresolved issue is the possibility of generalizing the results.

The result obtained in a specific population of patients after a stroke cannot automatically justify its use in healthy individuals, children, patients with unrelated neurological disorders, or under other treatment conditions.

Terminal points, initial risk, and an acceptable benefit-to-risk ratio can be very different.

The same applies to different routes of administration and formulations, even if the trade name remains unchanged.

A significant limitation is also the diversity of the studies themselves.

The individual publications cover acute stroke, chronic brain diseases, seizure models, or other neurological issues.

They can use different preparations, routes of administration, endpoints, and observation periods.

Combining them into a single claim about the overall benefits for the brain blurs these differences.

It is also necessary to distinguish the number of publications from the number of independent clinical studies.

Several reports may come from one group of participants.

Record numbers in the database should not be presented as numbers of independent clinical trials without checking the investigators, recruitment deadlines, number of participants, and the study design.

Reliance on abstract summaries alone constitutes another limitation of the assessment of the evidence.

A positive conclusion may omit information necessary to assess the concealment of participant allocation, data loss during observation, previously defined endpoints, and the method of collecting information on adverse events.

Any lack of details should be reported as a limitation of the assessment, and not automatically interpreted as evidence of the correct or incorrect conduct of the study.

In the case of a heterogeneous preparation, the consistency of the composition between batches and evidence of exposure to relevant components remain unresolved or not fully characterized issues.

The likely effect of the mixture does not explain which components are important, whether all series are equivalent, or whether the results of one formulation can be transferred to another.

Claims about safety require the same level of care as claims about effectiveness.

Small or short-term studies cannot rule out rare events or confirm the suitability of the product for all age groups and conditions.

The manufacturer's statements regarding extensive experience should not replace transparent data on adverse events.

Evidence should be summarized separately for each indication, clearly presenting the actual comparator group and the existing uncertainties.

Frequently asked questions about Cortexin

1. Does Cortexin mean one of the defined substances?

A commercial preparation means a polypeptide complex, not a single molecule with a specific sequence. In basic studies, a separate natural protein called cortexin also exists. Therefore, the context and identity of the material are essential before a publication is considered evidence for a commercial product. 1 2 During literature selection, the name should be associated with the product specification or the identified biological protein. Otherwise, the search result may be assigned to the wrong entity. This is especially important when comparing clinical reports with older publications in the field of molecular biology.

2. What do the available studies on Cortexin confirm?

They confirm that the preparation has been studied in neurological clinical trials involving humans and in preclinical models, and some publications report positive results. However, they do not confirm all the declared neurological applications or the equivalence of the different formulations. The conclusions should relate to the study design, the population, and the measured outcome. 4 6 The difference between the reported favorable outcome and the reliable estimate of the benefits depends on randomization, blinding, care in the comparison group, previously defined endpoints, and completeness of observation. Studies involving humans and animal experiments should be summarized separately, clearly presenting the uncertainties.

3. Is Cortexin a synthetic peptide?

No. The documentation analyzed by the manufacturer describes a complex polypeptide of tissue origin. It differs from a synthetic molecule with one defined sequence. The sequence assigned to the related experimental peptide should not be attributed to the entire preparation without direct evidence regarding the composition. 1 A single peptide isolated from the mixture could be studied separately, but this would not automatically mean that it is responsible for the activity of the original preparation. Evidence regarding the product requires the possibility of linking the results to the actually tested composition.

4. Is the natural protein cortexin the same as the drug?

The analyzed evidence does not confirm such equivalence. The 1993 publication concerns a separate membrane protein associated with neurons, whereas the commercial preparation is a mixture of tissue origin. The common name is a problem when selecting search results, not a basis for transferring molecular findings. 2 Even if the natural protein and the preparation are related to the brain cortex, the common anatomical context does not imply molecular identity. Proteins composed of 82 amino acid residues cannot be used as a basis for assigning a single sequence to an entire commercial complex.

5. Is Cortexin identical to Cerebrolysin?

No. These are distinctively identified preparations, even if they were tested in the same experiment. Direct comparison can provide valuable information, but does not prove a different composition or identical clinical effects. The results of each product should be interpreted in accordance with its identity and the research context. 3 Any comparison should determine whether the researchers used comparable amounts, routes of administration, and endpoints. Similarity of results in animals does not replace the clinical evaluation of a specific product or the formal evaluation of interchangeability.

6. Can Cortexin be attributed to a single summary pattern?

Not in a way that is justified for the entire mixture. The individual characterized components may have their own summary formulas, whereas the entire preparation requires a description of the composition and quality specifications. Assigning one formula to the entire complex would create an apparent precision, instead of improving identification. 1 The most informative description should include the distribution of the molecular units that make up the preparation, as well as relevant data characterizing the production batches. Providing a single formula for the entire extract would conceal its heterogeneity, instead of explaining it.

7. Have randomized studies involving humans been published?

Yes. The records found include randomized studies on stroke, including publications describing 62 and 272 patients. Their existence, quality, and applicability to clinical practice still need to be evaluated. Randomization is important, but it does not answer all questions about the risk of systematic error and the clinical significance. 4 5 Properly conducted randomization limits some types of selection error, but other safeguards are also necessary. Registration of the study, concealment of allocation, standardization of primary treatment, and transparent reporting of adverse events all contribute to the level of confidence in the results.

8. Did the study involving 490 patients include a group that did not receive Cortexin?

No. According to the description in the summary, both groups received active Cortexin, and the placebo injections were used to mask the alternative route of administration. This study compares formulations, rather than combining active treatment with the complete absence of the active drug. The conclusions should not be extended beyond the scope of this comparison. 6 Placebo procedures were used to hide information about the active route of administration, not to create a group that was not treated. Therefore, the study should be interpreted as a source of information about two ways of administering Cortexin, and not as a new study of its absolute efficacy compared to placebo.

9. Does the equivalence study of formulations prove overall effectiveness?

Not in itself. Demonstrating similarity between two formulations answers a different question than confirming benefits over a corresponding inactive comparator or standard care. Equivalence also requires a justified statistical margin and proper analysis. The same similar results do not resolve any of these issues. A conclusion of equivalence or lesser efficacy depends on a previously established clinical margin and appropriate analysis of confidence intervals. The absence of a statistically significant difference does not constitute an independent proof that the two formulations are equivalent.

10. Does the distribution study in mice prove the penetration of Cortexin into the human brain?

No. It provides evidence under the conditions of the mouse experiment and according to the measurement method used. Human exposure to intact, relevant components requires additional characterization, especially in the case of a mixture. The distribution of the radioactive marker should not be considered as identifying all active peptides in human brain tissue. 3 Radioactivity measurements can detect a signal associated with the preparation without identifying the intact molecules responsible for that signal. The blood-brain barrier penetration, tissue concentration, and functional effects require separate evidence that the mouse experiment does not provide.

11. Does binding to receptors confirm the clinical mechanism?

No. Binding is one of the stages of the evidence chain encompassing functional response, exposure, and clinical outcomes. In the case of a mixture, the additional challenge is identifying the component responsible for the interaction. The results of a receptor panel study can guide further experiments, but they do not prove how the effect observed in a patient is produced. 3 The binding result should be best viewed as a starting point for further research. Scientists still need to demonstrate the appropriate biological response and determine whether the components involved in the interaction reach their target under clinically relevant conditions.

12. Do the results of the research on seizures in animals confirm the treatment of epilepsy?

No. Experimental models of epilepsy respond to narrower questions under controlled conditions. Epilepsy in humans encompasses various disease syndromes, endpoints, and safety issues. Animal research contributes to science, but does not provide sufficient evidence for a broad claim of clinical treatment efficacy. 8 Electroencephalography models can provide information about neurobiology, but they do not reproduce the full range of epileptic syndromes in humans or confirm clinical seizure prevention. Such a claim would require studies in appropriately defined groups of patients.

13. Do the results of post-stroke studies confirm memory improvement in healthy people?

No. Returning to fitness after neurological injury and increasing cognitive abilities in healthy participants represent different indications. It cannot be assumed that the result obtained in one population will apply to another group with a different baseline level of functioning. The claim of benefits in healthy individuals requires independent, properly controlled evidence. Increasing cognitive abilities in healthy participants would require separate measurements and safety assessments. Improvement after injury is not equivalent to an increase beyond a healthy baseline level, and the endpoint for neurological rehabilitation cannot replace memory tests.

14. Does the amino acid list reveal all the active components of Cortexin?

No. The amino acid composition does not specify the order of amino acids in the sequence, the length of the chains, or the relative amount of individual molecules. A more detailed characterization is required to associate a component with an effect. Therefore, mixtures cannot be reduced to a list of their building blocks. Peptid sequencing and composition profiling differ from simply identifying the total amino acid content. Without information at the level of individual components, it is difficult to identify the responsible fraction or determine whether a subsequent series is chemically comparable.

15. Does commercial funding automatically invalidate the study?

No. Funding is an important context, but the value of the evidence is determined by methods, reporting, access to data, and the ability to replicate the results. The disclosed funding of a preclinical study justifies transparent presentation of this information, rather than automatic rejection or uncritical acceptance of the publication. Independent replication of the results would increase the level of trust. 3 Financial relationships should be disclosed so that readers can assess potential sources of bias. However, the most important factors remain methods, data, and repeatability. Confirmatory results by researchers independent of the original product development program would be particularly valuable.

16. Does the use of Cortexin in one country mean its approval in other countries?

No. Marketing approval applies to a specific product, jurisdiction, and conditions of use. The manufacturer’s description of the product as a prescription drug does not confirm approval worldwide. Before making a claim regarding a specific country, it is necessary to check the current official national registries. 1 Authorisation can also vary depending on the formulation, route of administration, population and indication within a single country. The manufacturer's documentation provides useful basic information, while final confirmation of regulatory status requires up-to-date data from the competent authority.

17. Which studies would most strengthen the scientific evidence regarding Cortexin?

The level of certainty would increase thanks to a transparent composition profile and independently repeated clinical studies, covering relevant endpoints and systematic safety reporting. Specifically important are previously defined analyses and appropriate comparison groups. This would allow to clarify both the composition of the preparation and the benefits that can be reliably attributed to it, if any. Future studies should, as far as possible, identify and control relevant peptide fractions, define a clinically significant primary endpoint and provide transparent observation. Independent replication of the results would help determine whether the observed effect is durable and whether it can be generalized beyond the original research environment.

Conclusions

The most reliable summary of the literature regarding Cortexin requires specifying the specific product, the population studied, the comparator group, and the measured outcome before discussing any reported benefits.

A randomized stroke study, a comparison of two active formulations, a receptor binding test, and a distribution experiment in mice provide different types of information.

They should not be combined into an unproven claim that Cortexin universally repairs the brain or increases its efficiency.

Cortexin is a trademark preparation containing a mixture of tissue-derived polypeptides, studied both in humans and in experimental systems. It is not a single peptide with a specific sequence.

An analysis of his literature requires careful distinction between publications with similar titles, checking for repeating populations of subjects, and taking into account differences between the comparison groups.

A correct interpretation separates the reported results from broader claims about brain regeneration, equivalence of formulations, or universal clinical benefits.

Educational and medical reservation

The article is intended for educational purposes only and does not constitute medical advice or recommendations for the use of Cortexin. It does not present dosage regimens, preparation or administration instructions.

Laboratory test results in animals and in specific groups of patients should not be automatically applied to other conditions or healthy individuals. They also do not confirm the quality or safety of a specific commercial product.

Cortexin’s registration status depends on the country and the form of the product. Information about approval should be checked in official registries, and treatment decisions should be discussed with qualified medical personnel.

References

1. GEROPHARM. (n.d.). Cortexin. Retrieved October 23, 2026, from https://geropharm.com/portfolio/nevrologiya-psihiatriya/korteksin
2. Coulter, P. M., Bautista, E. A., Margulies, J. E., & Watson, J. B. (1993). Identification of cortexin: A novel, neuron-specific, 82-residue membrane protein enriched in rodent cerebral cortex. Journal of Neurochemistry, 61(2), 756–759. https://doi.org/10.1111/j.1471-4159.1993.tb02183.x
3. Kurkin, D. V., Bakulin, D. A., Morkovin, E. I., Kalatanova, A. V., Makarenko, I. E., Dorotenko, A. R., Kovalev, N. S., Dubrovina, M. A., Verkholyak, D. V., Abrosimova, E. E., Smirnov, A. V., Shmidt, M. V., & Tyurenkov, I. N. (2021). Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLOS ONE, 16(7), e0254493. https://doi.org/10.1371/journal.pone.0254493
4. Skoromets, A. A., Stakhovskaia, L. V., Belkin, A. A., Shekhovtsova, K. V., Kerbikov, O. B., Burenchev, D. V., Gavrilova, O. V., & Skvortsova, V. I. (2008). [New possibilities of neuroprotection in the treatment of ischemic stroke]. Journal of Neurology and Psychiatry named S. S. Korsakov, Suppl 22, 32–38. https://pubmed.ncbi.nlm.nih.gov/19431244/
5. Aliferova, V. M., Dadasheva, M. N., Doronin, B. M., Kovalenko, A. V., Lokshtanova, T. M., Martynov, M. Iu., Meshkova, K. S., Salimov, K. A., Stakhovskaia, L. V., Chefranova, Zh. Iu., & Shamalov, N. A. (2014). [Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke]. Journal of Neurology and Psychiatry named S. S. Korsakov, 114(4), 41–46. https://pubmed.ncbi.nlm.nih.gov/24874316/
6. Fedin, A. I., Khairova, E. N., Artyukov, O. P., Timchenko, L. V., Bazhenova, O. A., Gaiduk, N. V., & Zykov, M. V. (2025). [Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes]. Journal of Neurology and Psychiatry named S. S. Korsakov, 125(12), 60–67. https://doi.org/10.17116/jnevro202512512160
7. Ziganshina, L. E., Abakumova, T., Nurkhametova, D., & Ivanchenko, K. (2023). Cerebrolysin for acute ischemic stroke. Cochrane Database of Systematic Reviews, 2023(10), CD007026. https://doi.org/10.1002/14651858.CD007026.pub7
8. Aniol, V. A., Novitskaia, Iu., Borodina, T. N., Bukreeva, T. V., Lazareva, N. A., Moiseeva, Iu. V., Onufriev, M. V., Stepanichev, M. Iu., Iakovlev, A. A., Gekht, A. B., Granstrem, O. K., & Guliaeva, N. V. (2011). [Evaluation of antiepileptic effects of cortexin in a model of convulsions]. Journal of Neurology and Psychiatry named after S. S. Korsakov, 111(12), 68–73. https://pubmed.ncbi.nlm.nih.gov/22433813/
9. Shabanov, P. D., Lebedev, A. A., Stetsenko, V. P., Lavrov, N. V., Markov, S. V., & Vojeikov, I. V. (2007). Comparison of behavioral effects of cortexin and cerebrolysin injected into brain ventricles. Bulletin of Experimental Biology and Medicine, 143(4), 437–441. https://doi.org/10.1007/s10517-007-0150-7